Basic Desyrel Information

• INN (International Nonproprietary Name): Trazodone
• Brand Names Available In Canada (English): Not specified
• ATC Code: N06AX05
• Forms & Dosages: Tablets 50 mg, 100 mg, 150 mg, 300 mg; Oral solution 10 mg/mL; Capsules 50 mg, 100 mg (limited markets)
• Manufacturers In Canada (English): Not specified
• Registration Status In Canada (English): Not specified
• OTC / Rx Classification: Prescription-only

Availability & Price Landscape

Can I get desyrel at the big chains or online across Canada?

Trazodone is prescription-only in Canada and is most often dispensed as generic trazodone tablets by major pharmacy banners.

Large national chains such as Shoppers Drug Mart, Rexall and London Drugs routinely dispense generic trazodone and may order brand Desyrel on request.

In Quebec, Jean Coutu is a commonly used banner for prescription antidepressants and may stock similar options.

Stocking of specific brands or pack sizes depends on local formularies and supply agreements with manufacturers such as Teva, Sandoz and Mylan.

Licensed Canadian online pharmacies also sell trazodone by prescription, but provincial rules apply to dispensing and prescription verification.

Cross-border imports from the United States are practiced by some patients, but these carry regulatory, shipping and prescription-validity risks.

Typical packages are 10–30 tablets across strengths (50–300 mg), and price per tablet for generics generally ranges from about CAD $0.10 to $1.00 depending on strength and insurer.

Brand Desyrel costs more than generics and availability varies by province and pharmacy.

Provincial drug plans such as the Ontario Drug Benefit, BC PharmaCare and RAMQ determine patient copays and specific coverage for DIN‑identified products.

Contact links for major banners: Shoppers Drug Mart, Rexall, London Drugs, Jean Coutu.

Canadian Patient Insights & Satisfaction Levels

What are Canadians saying about trazodone on forums and review sites?

Conversations about trazodone appear on Reddit Canada communities, HealthBoards and regional Facebook support groups.

Common discussion topics include trazodone for sleep, dose-finding, daytime sedation and interactions with other antidepressants.

Many Canadian patients report improved sleep at low doses (25–100 mg) and relief for depressive symptoms at higher doses (150 mg and above).

Patients often prefer generic trazodone for cost reasons but may seek brand Desyrel or extended‑release formulations when specific formulations are desired.

• Reported Benefits: Improved sleep at low doses; antidepressant effects at higher doses; perceived lower sexual side-effect burden compared with some SSRIs.
• Reported Challenges: Next-day drowsiness, orthostatic dizziness in older adults, variable access across provinces, and occasional pharmacy stockouts.

Anonymous patient quote: "Low-dose trazodone helped my sleep when other sleep meds made me feel hungover."

Anonymous patient quote: "I had to ask my pharmacist to order Desyrel specifically for an extended-release option."

These real-world experiences highlight tolerability trade-offs and access concerns that pharmacists can help navigate.

Product Overview & Brand Variants

Which names and formats should a Canadian patient watch for?

The INN for the medicine is trazodone and most retail supplies in Canada are generic trazodone products.

International brand names include Desyrel and Oleptro in the United States and Trittico in parts of Europe.

• INN: Trazodone
• Common International Brands: Desyrel, Oleptro, Trittico
• DIN: Products that appear in Canada will carry a Drug Identification Number once approved; check the DIN to confirm formulation and strength.

Formulations sold internationally include tablets 50 mg, 100 mg, 150 mg and 300 mg, an oral solution (typically 10 mg/mL) and extended‑release options in some markets.

Health Canada classifies trazodone as prescription-only and pharmacists must verify a valid prescription and counsel patients before dispensing.

Indications In Local Canadian Medical Practice

What is trazodone officially used for, and how do clinicians use it off-label?

Health Canada approvals depend on manufacturer submissions and the product’s DIN; internationally trazodone is approved primarily for major depressive disorder.

In Canadian practice, prescribers follow product monographs and may use trazodone under its approved antidepressant indication when supported by DIN‑labelled products.

Off‑label use is common, especially low‑dose trazodone (25–100 mg at bedtime) for insomnia or sleep maintenance.

Off‑label prescribing should involve informed consent and monitoring, and some provincial formularies may limit reimbursement for off‑label indications.

How It Works In The Body

Why does a low dose make people sleepy while a higher dose treats depression?

Trazodone belongs to the serotonin antagonist and reuptake inhibitor class (SARI) and has multiple actions that affect mood and sleep.

It blocks certain serotonin receptors (notably 5‑HT2) and inhibits serotonin reuptake, which can improve mood over weeks.

Antihistaminic and alpha‑adrenergic blockade contribute to sedation and the risk of orthostatic hypotension.

The ATC code N06AX05 places trazodone among "other antidepressants."

• Primary Actions: Serotonin reuptake inhibition and 5‑HT2 receptor antagonism.
• Secondary Actions: H1 antihistamine blockade and alpha‑adrenergic antagonism (sedation, dizziness risk).

Think of low doses as enough to produce sedation through antihistamine and receptor effects, while higher and sustained dosing supports serotonin modulation for antidepressant benefit.

Dosage & Administration

How should trazodone be started and adjusted for different patients?

For major depressive disorder in adults, a common starting point is around 150 mg/day in divided doses with outpatient maintenance up to 400 mg/day and inpatient titration sometimes higher.

For insomnia, clinicians commonly use low off‑label doses of 25–100 mg at bedtime, usually not exceeding 150 mg.

Elderly patients require lower starting doses and slower titration because of sedation and orthostatic hypotension risks.

Hepatic or renal impairment may require dose reductions and closer monitoring according to the product monograph tied to the product’s DIN.

Children are not approved for trazodone use.

When stopping trazodone, taper gradually to reduce withdrawal risk and follow prescriber instructions and pharmacist counselling under provincial regulations.

Contraindications & Side Effects

Who should not take trazodone, and what side effects matter most?

Absolute contraindications include known hypersensitivity to trazodone and concurrent or recent (within 14 days) MAOI therapy.

Some product monographs list the acute post‑myocardial infarction period as a contraindication.

• Common Side Effects: Drowsiness/sedation, dry mouth, dizziness, blurred vision, constipation, orthostatic hypotension, headache.
• Absolute Contraindications: Hypersensitivity to trazodone; recent MAOI therapy; acute recovery after myocardial infarction.

Report suspected adverse drug reactions to Health Canada via Canada Vigilance and consult a pharmacist if worrying symptoms appear.

Be cautious with interactions, notably strong CYP3A4 inhibitors and other serotonergic drugs.

Comparable Medicines In Canada

What other drugs are used for depression or sleep that clinicians may consider instead of trazodone?

Alternatives include mirtazapine (Remeron), amitriptyline, sertraline (Zoloft) and paroxetine (Paxil), each with different trade‑offs.

Choose based on comorbidities, prior responses and provincial formulary coverage.

• Pros Of Trazodone: Helpful sedating effect for patients with insomnia and depression; lower sexual dysfunction compared with some SSRIs.
• Cons Of Trazodone: Daytime sedation, orthostatic hypotension risk and off‑label sleep use requiring informed consent.

DINs and exact product comparisons should be verified via Health Canada’s Drug Product Database when prescribing or dispensing.

Current Research & Trends

What has recent research focused on for trazodone between 2022 and 2025?

Recent studies and reviews have centred on low‑dose trazodone for insomnia, comparative fall risk in older adults and real‑world safety compared with hypnotics and other antidepressants.

Meta‑analyses have examined the balance between short‑term sedation benefits and harms such as daytime somnolence and falls.

Canadian research places emphasis on geriatric safety, pharmacovigilance signals and prescribing patterns across provincial formularies.

Clinicians and pharmacists continue to monitor a renewed interest in trazodone for sleep versus guideline‑preferred options.

Ongoing observational studies and trials through 2025 aim to refine the risk‑benefit profile for different patient groups.

Research highlights: low‑dose sleep efficacy, fall risk data in older adults, and safety comparisons with benzodiazepines and z‑drugs.

Common Patient Questions In Canada

Patients often ask simple, practical questions about desyrel and access.

• Is a prescription required? Yes — trazodone is prescription-only and pharmacists will require a valid prescription for DIN‑identified products.
• Can I use trazodone for sleep? Many prescribers use low doses off‑label for insomnia; discuss benefits and risks with your clinician.
• Will it make me sleepy the next day? Daytime drowsiness is common; dose timing and size should be adjusted to reduce morning sedation.
• Is trazodone covered by provincial plans? Coverage depends on product DIN and provincial formularies such as Ontario Drug Benefit, BC PharmaCare and RAMQ; check with your pharmacist and insurer.
• What interactions should I watch for? Important interactions include MAOIs, other serotonergic drugs and strong CYP3A4 inhibitors.

For detailed monograph information and adverse event reporting, consult the product monograph tied to the product’s DIN and report concerns to Canada Vigilance.

Regulatory Status

How does Health Canada regulate trazodone and why does the DIN matter?

Health Canada evaluates pharmaceuticals for safety, efficacy and quality before issuing market authorisation.

Approved products receive a unique Drug Identification Number (DIN) that identifies formulation, strength and manufacturer.

Manufacturers must submit data to Health Canada for approval; Canadian availability follows those submissions and subsequent provincial listing decisions.

The DIN is essential for pharmacists, insurers and clinicians to confirm exact product details and coverage eligibility.

Patients can verify product monographs, recalls and approval details using the DIN on Health Canada’s Drug Product Database.

Reporting adverse events through Canada Vigilance supports ongoing pharmacovigilance and regulatory updates.

Approval Process Steps: Manufacturer Submission → Health Canada Review → DIN Assignment → Provincial Formulary Listing.

Visual Recommendations

Which visuals help patients and prescribers quickly understand desyrel use in Canada?

Suggested infographic blocks for a pharmacy product page include a dose ladder that maps insomnia doses (25–100 mg) to antidepressant doses (150–400+ mg) with colour‑coded cautions.

A provincial coverage map showing differences in generic and brand formulary coverage (Ontario Drug Benefit, BC PharmaCare, RAMQ) helps set patient expectations.

An interaction matrix with icons for MAOIs, CYP3A4 inhibitors and serotonergic agents provides rapid safety cues.

Safety badges such as "Prescription‑Only", "Check With Pharmacist" and "Report AEs To Canada Vigilance" support patient action.

Accessibility notes: include clear alt text for all images, high-contrast fonts and a printable DIN‑linked PDF monograph summary for patients.

Buying & Storage Advice

Where should Canadians buy desyrel and how should they store it?

Always use licensed pharmacies and present a valid prescription when required by regulation.

In‑store visits allow face‑to‑face counselling while online Canadian pharmacies offer convenience if they are registered with the appropriate provincial pharmacy college and dispense from within Canada.

Compare in‑store pricing with online promotions; generics are usually less expensive but insurer copays and manufacturer discounts affect out‑of‑pocket costs.

Cross‑border sourcing from the United States is done by some patients but carries customs, regulatory and formulation risks.

In our online pharmacy, desyrel is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Store trazodone at room temperature (15°C–30°C), protected from moisture and heat, and keep out of reach of children.

In Canadian winter weather, avoid leaving packages in unheated spaces where freezing could affect liquid formulations.

Tightly cap any liquid formulations and follow manufacturer storage instructions printed on the product label.

Guidelines For Proper Use

What should prescribers and pharmacists tell patients starting trazodone?

Counsel on the intended use—whether as an antidepressant or an off‑label sleep aid—and the expected timeline for effect.

Antidepressant benefit can take 4–6 weeks for full effect, while sleep improvements may occur sooner.

Warn patients about morning drowsiness, orthostatic precautions, and the need to avoid alcohol and other central nervous system depressants.

Advise against driving or operating heavy machinery until they know how trazodone affects them.

Monitor baseline blood pressure, cardiac history and concomitant serotonergic medications, plus hepatic and renal function in at‑risk patients.

Taper gradually when discontinuing to reduce withdrawal risk and document informed consent for off‑label sleep use when required by provincial guidelines.

Provide a printable counselling checklist covering dosing, side effects, interactions and when to seek urgent care.

Delivery Across Canada (English)